Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices traded up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 139 points (0.8%) at 17,996 as of Monday, March 9, 2015, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,624 issues advancing vs. 1,454 declining with 140 unchanged.

The Drugs industry as a whole closed the day down 0.3% versus the S&P 500, which was up 0.4%. Top gainers within the Drugs industry included

Oragenics

(

OGEN

), up 1.8%,

Recro Pharma

(

REPH

), up 36.8%,

Merus Labs International

TheStreet Recommends

(

MSLI

), up 2.4%,

Biostar Pharmaceuticals

(

BSPM

), up 4.2% and

Imprimis Pharmaceuticals

(

IMMY

), up 4.0%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Merus Labs International

(

MSLI

) is one of the companies that pushed the Drugs industry higher today. Merus Labs International was up $0.05 (2.4%) to $2.15 on light volume. Throughout the day, 16,090 shares of Merus Labs International exchanged hands as compared to its average daily volume of 36,000 shares. The stock ranged in a price between $2.11-$2.17 after having opened the day at $2.15 as compared to the previous trading day's close of $2.10.

Merus Labs International Inc., a specialty pharmaceutical company, engages in the acquisition and licensing of prescription medicines in the United States, Canada, and Europe. Merus Labs International has a market cap of $175.4 million and is part of the health care sector. Shares are up 27.0% year-to-date as of the close of trading on Friday. Currently there are no analysts who rate Merus Labs International a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Merus Labs International as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good.

Highlights from TheStreet Ratings analysis on MSLI go as follows:

  • MSLI's very impressive revenue growth greatly exceeded the industry average of 10.4%. Since the same quarter one year prior, revenues leaped by 69.8%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Despite the fact that it has already risen in the past year, there is currently no conclusive evidence that warrants the purchase or sale of this stock.
  • Net operating cash flow has remained constant at $3.19 million with no significant change when compared to the same quarter last year. Along with maintaining stable cash flow from operations, the firm exceeded the industry average cash flow growth rate of -11.57%.
  • MERUS LABS INTERNATIONAL INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, MERUS LABS INTERNATIONAL INC reported poor results of -$0.16 versus -$0.05 in the prior year.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Pharmaceuticals industry and the overall market, MERUS LABS INTERNATIONAL INC's return on equity significantly trails that of both the industry average and the S&P 500.

You can view the full analysis from the report here:

Merus Labs International Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close,

Recro Pharma

(

REPH

) was up $1.21 (36.8%) to $4.50 on heavy volume. Throughout the day, 481,149 shares of Recro Pharma exchanged hands as compared to its average daily volume of 20,100 shares. The stock ranged in a price between $3.56-$4.77 after having opened the day at $3.72 as compared to the previous trading day's close of $3.29.

Recro Pharma has a market cap of $25.4 million and is part of the health care sector. Shares are up 15.0% year-to-date as of the close of trading on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Oragenics

(

OGEN

) was another company that pushed the Drugs industry higher today. Oragenics was up $0.02 (1.8%) to $1.16 on light volume. Throughout the day, 23,650 shares of Oragenics exchanged hands as compared to its average daily volume of 37,800 shares. The stock ranged in a price between $1.11-$1.22 after having opened the day at $1.14 as compared to the previous trading day's close of $1.14.

Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. Oragenics has a market cap of $39.4 million and is part of the health care sector. Shares are up 22.5% year-to-date as of the close of trading on Friday. Currently there are no analysts who rate Oragenics a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Oragenics as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on OGEN go as follows:

  • OGEN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 69.89%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income increased by 89.0% when compared to the same quarter one year prior, rising from -$9.33 million to -$1.03 million.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ORAGENICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The revenue fell significantly faster than the industry average of 35.5%. Since the same quarter one year prior, revenues fell by 20.6%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • Net operating cash flow has increased to -$1.10 million or 44.14% when compared to the same quarter last year. Despite an increase in cash flow, ORAGENICS INC's average is still marginally south of the industry average growth rate of 50.58%.

You can view the full analysis from the report here:

Oragenics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.